Wortmannin and Triciribine target the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways. By inhibiting these pathways, they may exert control over cellular processes such as growth, survival, and metabolism, which could, in turn, influence the activity or expression of LOC728809. Similarly, ZM-447439's action as an Aurora kinase inhibitor can disrupt cell cycle progression, potentially affecting proteins that are regulated during mitosis, which might include LOC728809. Erastin, known for inducing ferroptosis by inhibiting system x(c)-, alters the cellular redox homeostasis, which could lead to changes in the function or stability of redox-sensitive proteins like LOC728809. Meanwhile, mTOR inhibitors such as Torin 1, akin to Rapamycin, may downregulate protein synthesis pathways, possibly leading to a decrease in LOC728809 synthesis if it is indeed produced in an mTOR-dependent manner. In the realm of growth factor signaling, Gefitinib, an EGFR inhibitor, potentially affects the stability or activity of proteins that are regulated by this receptor tyrosine kinase, which could include LOC728809 if it is part of the EGFR pathway. BML-275 inhibition of AMPK might modify the energy status of the cell, impacting proteins that are sensitive to such metabolic shifts.
Inhibitors like GSK690693 also target AKT, further reinforcing the suppression of AKT-mediated signaling, while compounds such as Blebbistatin and Y-27632 disrupt cytoskeletal dynamics by inhibiting myosin II and ROCK, respectively. Such disruption could influence cellular processes that rely on the cytoskeleton, possibly affecting the localization or function of LOC728809 if it interacts with these structures. Protein kinase C, targeted by Go6983, is implicated in various signaling pathways, and its inhibition can modulate multiple proteins, potentially including LOC728809. Finally, Tunicamycin disrupts N-linked glycosylation, a post-translational modification critical for proper protein folding and stability. If LOC728809 is glycosylated, its stability and function could be impacted by such an inhibitor.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, which may alter signaling pathways that LOC728809 is involved in, thus affecting its activity indirectly. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor, potentially decreases downstream signaling that could modulate LOC728809 activity or expression. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor, can affect cell cycle regulation, possibly influencing LOC728809 if it is cell cycle-related. | ||||||
Erastin | 571203-78-6 | sc-205677 sc-205677A | 5 mg 50 mg | $372.00 $1614.00 | 1 | |
Induces ferroptosis by inhibiting system x(c)-, potentially affecting redox status, which could influence LOC728809 activity. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
mTOR inhibitor, like Rapamycin, can downregulate protein synthesis pathways including those associated with LOC728809. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, may affect growth factor signaling pathways that regulate LOC728809 activity or stability. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Inhibits AMPK, potentially modifying the energy status of the cell, which could indirectly impact LOC728809 function. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
AKT inhibitor, potentially reduces AKT-mediated signaling, which may influence LOC728809 if it's part of this pathway. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Inhibits myosin II, which could affect cytoskeletal dynamics and potentially impact cellular processes involving LOC728809. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Protein kinase C inhibitor, can affect multiple signaling pathways and may indirectly modulate LOC728809's activity. | ||||||